Description
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 7
Primary Industries
- Drugs
- Drug Discovery
- Diagnostic
- Pain
- Nerve
- Technical Know How
- Bacterial Infection
- Disease
- Central Nervous System
- Delivery
- Therapeutic
- Pharmaceuticals
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 380857
Licensor grants to the Licensee of France an exclusive license, with the right to sublicense, under the Licensor Patents claiming such Licensor Information, and to use such Licensor Information, in each case to develop, register, manufacture, use, distribute, sell, offer for sale and have sold the Licensor Product in the Rest of the World in such indication within the Field.
— the immediate release formulation in capsule form containing 25 mg and 50 mg of Milnacipran (the IR Formulation), and
— the slow release formulation covered by Pierre Fabre Patents containing 120 mg of Milnacipran (the SR Formulation).
Licensors patents include
Methods of treating fibromyalgia syndrome;
Methods of treating Chronic Fatigue Syndrome;
Methods of treating attention deficit hyperactivity disorder;
Methods of treating visceral pain syndromes;
Methods of treating functional somatic disorders;
Methods of assessing the level of a subjective symptom;
Treatment of Pain Associated Depression;
Dosage escalation of Milnacipran;
Treatment of Sleep Disorders;
Increased and divided daily dosage of anti-depressant to treat pain and functional somatic symptons; and,
Treatment of cognitive disfunctions.
By this restated agreement, Field shall mean any and all indications.
IPSCIO Record ID: 372573
Licensor of France grants an exclusive license, with the right to sublicense, under the Licensed Technology to develop, register, use, distribute, sell, offer for sale, have sold and import the Licensed Product in the Licensed Territory in the Field.
Licensor further grants a license to use Licensor Know-How and Licensor Patents, to the extent necessary to formulate or have the API formulated into Bulk Licensed Product and package Bulk Licensed Product into Finished Licensed Product, solely for sale of Licensed Product in the Licensed Territory.
Licensee shall develop the Licensed Product in the Licensed Territory at its own expense, and in accordance with the initial development plan, and, Licensee shall also use commercially reasonable efforts to achieve the following events with respect to a Licensed Product in fibromyalgia syndrome or FMS in the United States.
Licensed Product shall mean any product, including a Licensee Product or product containing a Licensee Formulation, containing Milnacipran as an active ingredient, in any formulation and through any mode of administration, that incorporates or uses the Licensed Technology or the manufacture, use or sale of which is within the scope of any claim of the Licensor Patents
— the immediate release formulation in capsule form containing 25 mg and 50 mg of Milnacipran (the IR Formulation), and
— the slow release formulation covered by Pierre Fabre Patents containing 120 mg of Milnacipran (the SR Formulation).
Fibromyalgia is a disorder characterized by widespread musculoskeletal pain accompanied by fatigue, sleep, memory and mood issues. Researchers believe that fibromyalgia amplifies painful sensations by affecting the way your brain and spinal cord process painful and nonpainful signals.
By this restated agreement, Field shall mean any and all indications.
IPSCIO Record ID: 203476
Licensee hereby grants to Licensor during the R&D Term a non-exclusive, non-sublicensable, non-transferable license to the Licensee for use by Licensor only for the performance of its obligations under this Agreement. Licensor agrees that it shall not use the Licensee for any other purposes.
Licensee Patents shall mean, to the extent necessary or useful for the development of Reformulated Products or New Products or otherwise for purposes of the R&D Plan, (a) all foreign and domestic (i) patents issued or existing as of the Effective Date which Licensee Controls; (ii) patents issuing from patent applications that are pending as of the Effective Date.
Reformulated Product shall mean any Product which is developed by Licensor under this Agreement and contains milnacipran in a formulation that is different than the Existing Product, but that does not meet the criteria for a New Product.
Milnacipran is immediate release formulation in capsule form containing 25 mg and 50 mg of milnacipran and the existing slow release fo1mulation containing 120 mg of milnacipran, as set forth in PCT published international application WO 98/08495.
IPSCIO Record ID: 367296
(a) All applicable laws and regulations, including, without limitation, the requirements of federal law as pertain to the manufacture of products within the United States;
(b) All applicable rules of the Funding Agencies which have provided funding to Licensor or to any of its employees (including any of the Inventors) for the development of the Patent Rights and Technical Information; and
(c) The following non-exclusive rights to the Patent Rights and Technical Information, which are retained by Licensor within the Field of Use
(i) the right to submit for publication the scientific findings from research conducted by or through Licensor or its investigators (including the Inventors) related to the Patent Rights and the Technical Information; and
(ii) the right (A) to use any tangible or intangible information contained in the Patent Rights or the Technical Information or any Improvements (so long as Licensor shall treat such information as Confidential Information and maintain its confidentiality in accordance with Section 10 hereof), for Licensor’s internal non-commercial scientific, research, internal teaching, non-profit clinical research and other educationally-related and non-commercial (except for charges to its own patients) clinical purposes, where clinical use does not involve a third party funding grant to commercialize such information, and (B) to obtain research funding for further study and development thereof from governmental and other nonprofit organizations (including grant applications).
(d) Notwithstanding any other provision hereof to the contrary, all rights to the Patent Rights, Technical Information and Improvements outside of the Field of Use are retained by Licensor. Furthermore, this Agreement confers no license or rights by implication, estoppel, or otherwise under any patent applications or patents of Licensor other than Patent Rights regardless of whether such patents are dominant or subordinate to Patent Rights.
6,861,053 – Methods of diagnosing or treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth
6,805,852 – Methods of diagnosing irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth
7,056,686 – Method of diagnosing fibromyalgia caused by small intestinal bacterial overgrowth
Archaea is a group of primitive prokaryotes that based on their distinct characteristics form a separate domain from bacteria and eukaryotes. Bacteria are single-celled primitive organisms that form a domain of organisms diverse in shape, size, structure, and even habitats.
IPSCIO Record ID: 266736
Licensor grants to the extent of the Licensed Territory a nonexclusive license to use the Licensed Technology as necessary to exploit all rights granted with respect to the patent rights in the Licensed Field, with the right to sublicense.
Rifaximin means rifaximin, any pharmaceutical equivalents, salts and derivatives thereof.
IPSCIO Record ID: 315667
Licensor is primarily focusing on the repurposing of safe and (cost-)effective compounds to treat Attention Deficit/HyperActivity Disorder (ADHD), sleep disorders and cognitive impairment.
Licensee is an innovative biotechnology company engaged in the discovery and development of life-improving drug therapies to treat rare and complex central nervous system, or CNS, disorders, including narcolepsy, idiopathic hypersomnia and other rare sleep disorders, and of neurodevelopmental disorders, such as Attention Deficit Hyperactivity Disorder, or ADHD. CNS disorders are a diverse group of conditions that include neurological, psychiatric, and substance use disorders.
IPSCIO Record ID: 25935
Pursuant to this agreement, the parties agree to a royalty payment for the right to sublicense the technology. French Licensor hereby grants.
Licensor has developed Milnacipran for the treatment of depression and currently markets the IR Formulation itself or through licensees for the treatment of depression in certain territories outside the United States.
